Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Google Secures Pentagon AI Deal for Classified Projects 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
WEST LAFAYETTE, Ind., Feb. 16, 2016 -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that the company’s management team will present at the following upcoming healthcare conferences.
2016 RBC Capital Markets Global Healthcare Conference – Tuesday, Feb. 23, at 8:30 a.m. EST. The conference will be held at the New York Palace Hotel in New York City.
Cowen and Company 36th Annual Health Care Conference – Tuesday, Mar. 8, at 10:40 a.m. EST. The conference will be held at the Boston Marriott Copley Place.
Webcast information can be accessed under “Events & Presentations” in the Investors & News section of Endocyte’s website at www.endocyte.com. All webcasts will be archived shortly after each live event and a replay will be available on the Company’s website for 90 days following the conference.
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer and other serious diseases. Endocyte uses its proprietary drug conjugation technology to create novel SMDCs and companion imaging agents for personalized targeted therapies. The company’s SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. For additional information, please visit Endocyte’s website at www.endocyte.com.
Contacts: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected]
